OLMA
Price:
$11.86
Market Cap:
$679.18M
Olema Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies for women's cancers. Its lead product candidate is OP-1250, an estrogen receptor (ER) antagonist and a selective ER degrader, which is in Phase 1/2 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive, human epidermal growth factor receptor 2-negative breast cancer. The company was formerly known as CombiThera, Inc. and changed its name to Olema Pharmaceuticals, Inc. in March 2009. Olema Pharmaceuticals, Inc. was incorporated in 2006 and is headquartered in San Francisco, California.[Read more]
Industry
Biotechnology
IPO Date
2020-11-19
Stock Exchange
NASDAQ
Ticker
OLMA
According to Olema Pharmaceuticals, Inc.’s latest financial reports and current stock price. The company's current Enterprise Value is 664.25M. This represents a change of 14.09% compared to the average of 582.23M of the last 4 quarters.
The mean historical Enterprise Value of Olema Pharmaceuticals, Inc. over the last ten years is 823.14M. The current 664.25M Enterprise Value has changed 7.97% with respect to the historical average. Over the past ten years (40 quarters), OLMA's Enterprise Value was at its highest in in the September 2020 quarter at 1.71B. The Enterprise Value was at its lowest in in the June 2020 quarter at 0.
Average
823.14M
Median
628.19M
Minimum
76.85M
Maximum
1.97B
Discovering the peaks and valleys of Olema Pharmaceuticals, Inc. Enterprise Value, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.
Maximum Annual Increase = 639.99%
Maximum Annual Enterprise Value = 1.97B
Minimum Annual Increase = -94.46%
Minimum Annual Enterprise Value = 76.85M
Year | Enterprise Value | Change |
---|---|---|
2023 | 568.69M | 639.99% |
2022 | 76.85M | -10.62% |
2021 | 85.99M | -94.46% |
2020 | 1.55B | -21.18% |
2019 | 1.97B | 186.22% |
The current Enterprise Value of Olema Pharmaceuticals, Inc. (OLMA) is greater than its 3-year, less than than its 5-year, and less than than its 10-year historical averages
3-year avg
243.84M
5-year avg
850.23M
10-year avg
823.14M
Olema Pharmaceuticals, Inc.’s Enterprise Value is less than Sana Biotechnology, Inc. (796.24M), less than Cullinan Oncology, Inc. (810.70M), greater than aTyr Pharma, Inc. (138.44M), greater than Zentalis Pharmaceuticals, Inc. (272.28M), greater than Molecular Partners AG (57.25M), greater than Mineralys Therapeutics, Inc. (603.45M), greater than AN2 Therapeutics, Inc. (5.46M), less than Pharvaris N.V. (844.28M), greater than PepGen Inc. (174.61M), less than Gracell Biotechnologies Inc. (5.47B), greater than Theseus Pharmaceuticals, Inc. (138.26M), greater than Monte Rosa Therapeutics, Inc. (478.04M), greater than Design Therapeutics, Inc. (258.23M), less than Erasca, Inc. (691.95M), less than Disc Medicine, Inc. (1.23B), greater than Larimar Therapeutics, Inc. (453.31M), greater than Fennec Pharmaceuticals Inc. (113.94M), greater than Orchestra BioMed Holdings, Inc. (184.26M), greater than Nuvectis Pharma, Inc. (99.58M), less than Centessa Pharmaceuticals plc (1.76B),
Company | Enterprise Value | Market cap |
---|---|---|
796.24M | $836.47M | |
810.70M | $922.99M | |
138.44M | $131.12M | |
272.28M | $265.23M | |
57.25M | $247.30M | |
603.45M | $671.31M | |
5.46M | $32.23M | |
844.28M | $1.29B | |
174.61M | $221.28M | |
5.47B | $989.87M | |
138.26M | $181.50M | |
478.04M | $542.54M | |
258.23M | $301.22M | |
691.95M | $810.79M | |
1.23B | $1.73B | |
453.31M | $483.02M | |
113.94M | $127.22M | |
184.26M | $206.52M | |
99.58M | $117.70M | |
1.76B | $1.80B |
One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Olema Pharmaceuticals, Inc. using the financials and key metrics that matter to you in a single view.
The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:
Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.
Get your free trial here.
The easiest way to analyze a company like Olema Pharmaceuticals, Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.
Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.
Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.
What is the Enterprise Value?
How can you use the Enterprise Value?
What is Olema Pharmaceuticals, Inc.'s Enterprise Value?
What is the highest Enterprise Value for Olema Pharmaceuticals, Inc. (OLMA)?
What is the 3-year average Enterprise Value for Olema Pharmaceuticals, Inc. (OLMA)?
What is the 5-year average Enterprise Value for Olema Pharmaceuticals, Inc. (OLMA)?
How does the current Enterprise Value for Olema Pharmaceuticals, Inc. (OLMA) compare to its historical average?